Innovative HIF-2α Inhibitor Combination Strategies in Metastatic Clear Cell Renal Cell Carcinoma
Abstract
HIF-2α inhibitors such as belzutifan have reshaped the treatment landscape for metastatic clear cell renal cell carcinoma. Given the intricate roles between the HIF-2α and angiogenesis pathways, novel combinations of HIF-2α inhibitors with tyrosine kinase inhibitors are currently under investigation and may represent a promising treatment strategy for this disease.
Fields of Study & Subjects
Renal cell carcinoma treatment
Cancer
Hypoxia
and Metabolism
Hepatocellular Carcinoma Treatment and Prognosis
Publication details
- Journal / source
- Default Digital Object Group
- Publication date
- 18 February 2026
- Language
- EN
- Document type
- Dataset